[HTML][HTML] Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study
I Gentile, R Scotto, N Schiano Moriello, B Pinchera… - Vaccines, 2022 - mdpi.com
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
[PDF][PDF] Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study. Vaccines 2022, 10, 1731
I Gentile, R Scotto, N Schiano Moriello, B Pinchera… - 2022 - academia.edu
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.
I Gentile, R Scotto, B Pinchera, R Villari, E Trucillo… - Vaccines, 2022 - europepmc.org
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
[PDF][PDF] Federico II COVID team
I Gentile, R Scotto, NS Moriello, B Pinchera, R Villari… - scholar.archive.org
Molnupiravir and Nirmatrelvir are the first available oral antivirals (OA) active against SARS-
CoV-2. However, the trials evaluating the efficacy of OAs involved patients unvaccinated and …
CoV-2. However, the trials evaluating the efficacy of OAs involved patients unvaccinated and …
[HTML][HTML] Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
I Gentile, R Scotto, NS Moriello, B Pinchera, R Villari… - Vaccines, 2022 - ncbi.nlm.nih.gov
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life study
I Gentile, R Scotto, NS Moriello, B Pinchera, R Villari… - medRxiv, 2022 - medrxiv.org
Molnupiravir and Nirmatrelvir are the first available oral antivirals (OA) active against SARS-
CoV-2. However, the trials evaluating the efficacy of OAs involved patients unvaccinated and …
CoV-2. However, the trials evaluating the efficacy of OAs involved patients unvaccinated and …
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
I Gentile, R Scotto, N Schiano Moriello, B Pinchera… - VACCINES, 2022 - iris.unina.it
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study.
I Gentile, R Scotto, NS Moriello, B Pinchera, R Villari… - 2022 - cabidigitallibrary.org
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study.
I Gentile, R Scotto, N Schiano Moriello… - Vaccines, 2022 - search.ebscohost.com
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
I Gentile, R Scotto, NS Moriello, B Pinchera… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …